Paper34849495
The emergence of powerful oral anti-COVID-19 drugs in the post-vaccine era.
Fan H and 4 others. Lancet Microbe, 2022. Cited by 40 papers, by iCite.
Cite this record
ConductScience Library. The emergence of powerful oral anti-COVID-19 drugs in the post-vaccine era. Papers, record 34849495. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34849495
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics4
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| COVID-19 | Major topic |
| Vaccines | Major topic |
| Humans | |
| SARS-CoV-2 |
Source PubMed
References4
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32253226 | An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. | Sci Transl Med | 2020 | https://conductscience.org/library/papers/32253226 | PubMed |
| 2 | 33961695 | β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells. | J Infect Dis | 2021 | https://conductscience.org/library/papers/33961695 | PubMed |
| 3 | 34310217 | Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs. | Antimicrob Agents Chemother | 2021 | https://conductscience.org/library/papers/34310217 | PubMed |
| 4 | 34518697 | Molnupiravir: coding for catastrophe. | Nat Struct Mol Biol | 2021 | https://conductscience.org/library/papers/34518697 | PubMed |
Cited by28
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 40 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 38915977 | Real-World Efficacy of Ensitrelvir in Hospitalized Patients With COVID-19 in Japan: A Retrospective Observational Study. | Cureus | 2024 | https://conductscience.org/library/papers/38915977 | PubMed |
| 38361624 | Bioluminescence imaging reveals enhanced SARS-CoV-2 clearance in mice with combinatorial regimens. | iScience | 2024 | https://conductscience.org/library/papers/38361624 | PubMed |
| 37841365 | Taking stock of the mutations in human SARS-CoV-2 spike proteins: From early days to nearly the end of COVID-19 pandemic. | Curr Res Struct Biol | 2023 | https://conductscience.org/library/papers/37841365 | PubMed |
| 37542245 | Metallic nanoplatforms for COVID-19 diagnostics: versatile applications in the pandemic and post-pandemic era. | J Nanobiotechnology | 2023 | https://conductscience.org/library/papers/37542245 | PubMed |
| 37041762 | COVID-19 in early 2023: Structure, replication mechanism, variants of SARS-CoV-2, diagnostic tests, and vaccine & drug development studies. | MedComm (2020) | 2023 | https://conductscience.org/library/papers/37041762 | PubMed |
| 37020822 | The shift of percent excess mortality from zero-COVID policy to living-with-COVID policy in Singapore, South Korea, Australia, New Zealand and Hong Kong SAR. | Front Public Health | 2023 | https://conductscience.org/library/papers/37020822 | PubMed |
| 36770656 | Coronavirus Inhibitors Targeting nsp16. | Molecules | 2023 | https://conductscience.org/library/papers/36770656 | PubMed |
| 36698809 | Luteolin-rich fraction from Perilla frutescens seed meal inhibits spike glycoprotein S1 of SARS-CoV-2-induced NLRP3 inflammasome lung cell inflammation via regulation of JAK1/STAT3 pathway: A potential anti-inflammatory compound against inflammation-induced long-COVID. | Front Med (Lausanne) | 2022 | https://conductscience.org/library/papers/36698809 | PubMed |
| 36560775 | The Effect of Preventive Measures and Vaccination against SARS-CoV-2 on the Infection Risk, Treatment, and Hospitalization: A Cross-Sectional Study of Algeria. | Viruses | 2022 | https://conductscience.org/library/papers/36560775 | PubMed |
| 36105233 | Nucleic acid strategies for infectious disease treatments: The nanoparticle-based oral delivery route. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/36105233 | PubMed |
| 35992968 | Sub-lineages of the SARS-CoV-2 Omicron variants: Characteristics and prevention. | MedComm (2020) | 2022 | https://conductscience.org/library/papers/35992968 | PubMed |
| 35862736 | Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant. | Clin Microbiol Rev | 2022 | https://conductscience.org/library/papers/35862736 | PubMed |
| 35807916 | Cyanidin-3-O-glucoside and Peonidin-3-O-glucoside-Rich Fraction of Black Rice Germ and Bran Suppresses Inflammatory Responses from SARS-CoV-2 Spike Glycoprotein S1-Induction In Vitro in A549 Lung Cells and THP-1 Macrophages via Inhibition of the NLRP3 Inflammasome Pathway. | Nutrients | 2022 | https://conductscience.org/library/papers/35807916 | PubMed |
| 35779085 | Pandemic COVID-19, an update of current status and new therapeutic strategies. | Naunyn Schmiedebergs Arch Pharmacol | 2022 | https://conductscience.org/library/papers/35779085 | PubMed |
| 35726542 | OMICRON: Virology, immunopathogenesis, and laboratory diagnosis. | J Gene Med | 2022 | https://conductscience.org/library/papers/35726542 | PubMed |
| 35711421 | Overview of Breastfeeding Under COVID-19 Pandemic. | Front Immunol | 2022 | https://conductscience.org/library/papers/35711421 | PubMed |
| 35663284 | Fluorine in Medicinal Chemistry: In Perspective to COVID-19. | ACS Omega | 2022 | https://conductscience.org/library/papers/35663284 | PubMed |
| 35504917 | COVID-19 vaccine development: milestones, lessons and prospects. | Signal Transduct Target Ther | 2022 | https://conductscience.org/library/papers/35504917 | PubMed |
| 35489042 | Promising Therapeutic Approach for SARS-CoV-2 Infections by Using a Rutin-Based Combination Therapy. | ChemMedChem | 2022 | https://conductscience.org/library/papers/35489042 | PubMed |
| 35444647 | Molnupiravir and Its Antiviral Activity Against COVID-19. | Front Immunol | 2022 | https://conductscience.org/library/papers/35444647 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ACE2 | 59272 | PubTator's text mining | https://conductscience.org/library/genes/59272 | NCBI Gene |
| TMPRSS2 | 7113 | PubTator's text mining | https://conductscience.org/library/genes/7113 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34849495
GET https://conductscience.org/api/papers/v1/34849495/cited_by?page=2